Format

Send to

Choose Destination
Acta Neuropathol Commun. 2016 Jul 19;4(1):74. doi: 10.1186/s40478-016-0345-0.

Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation.

Author information

1
University of Lille, Inserm, CHU-Lille, F-59000, Lille, France.
2
Sorbonne Universités, UPMC Univ Paris 06, Hôpital Pitié-Salpêtrière, Paris, France.
3
INSERM UMRS_1127, Hôpital Pitié-Salpêtrière, Paris, France.
4
CNRS UMR_7225, Hôpital Pitié-Salpêtrière, Paris, France.
5
AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.
6
ICM, Hôpital Pitié-Salpêtrière, Paris, France.
7
University of Lille, Inserm, CHU-Lille, F-59000, Lille, France. valerie.buee-scherrer@inserm.fr.
8
Université Artois, Faculté Jean Perrin, F-62307, Lens, France. valerie.buee-scherrer@inserm.fr.
9
Inserm UMRS1172 - Alzheimer & Tauopathies, Faculty of Medecine-Research Pole, University of Lille, Place de Verdun, F-59045, Lille cedex, France. valerie.buee-scherrer@inserm.fr.

Abstract

Reduction of Tau protein expression was described in 2003 by Zhukareva et al. in a variant of frontotemporal lobar degeneration (FTLD) referred to as diagnosis of dementia lacking distinctive histopathology, then re-classified as FTLD with ubiquitin inclusions. However, the analysis of Tau expression in FTLD has not been reconsidered since then. Knowledge of the molecular basis of protein aggregates and genes that are mutated in the FTLD spectrum would enable to determine whether the "Tau-less" is a separate pathological entity or if it belongs to an existing subclass of FTLD. To address this question, we have analyzed Tau expression in the frontal brain areas from control, Alzheimer's disease and FTLD cases, including FTLD- Tau (MAPT), FTLD-TDP (sporadic, FTLD-TDP-GRN, FTLD-TDP-C9ORF72) and sporadic FTLD-FUS, using western blot and 2D-DIGE (Two-Dimensional fluorescence Difference Gel Electrophoresis) approaches. Surprisingly, we found that most of the FTLD-TDP-GRN brains are characterized by a huge reduction of Tau protein expression without any decrease in Tau mRNA levels. Interestingly, only cases affected by point mutations, rather than cases with total deletion of one GRN allele, seem to be affected by this reduction of Tau protein expression. Moreover, proteomic analysis highlighted correlations between reduced Tau protein level, synaptic impairment and massive reactive astrogliosis in these FTLD-GRN cases. Consistent with a recent study, our data also bring new insights regarding the role of progranulin in neurodegeneration by suggesting its involvement in lysosome and synaptic regulation. Together, our results demonstrate a strong association between progranulin deficiency and reduction of Tau protein expression that could lead to severe neuronal and glial dysfunctions. Our study also indicates that this FTLD-TDP-GRN subgroup could be part as a distinct entity of FTLD classification.

KEYWORDS:

Astrogliosis; Frontotemporal lobar degeneration; Progranulin; Synaptic impairment; Tau protein

PMID:
27435172
PMCID:
PMC4952067
DOI:
10.1186/s40478-016-0345-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center